SCHEMBL3087959

SCHEMBL3087959

Cc1ccc(S(=O)(=O)NC(=O)C(CC2CC2)C(=O)N(c2ccc(F)cc2)C(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.45
▸ ERBB2 P04626 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.43
▸ TP53 P04637 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.41
▸ KMT2A Q03164 3/20 0.39
▸ TAS2R14 Q9NYV8 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ TSHR P16473 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ PPARG P37231 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092840 0.91 EGFR (0.44) EGFRERBB2ALDH1A1KMT2AMEN1
SCHEMBL3083883 0.90 EGFR (0.48) EGFRERBB2ALDH1A1KMT2ATAS2R14
SCHEMBL3097794 0.89 BCL2L1 (0.41) KMT2AMEN1USP30
SCHEMBL3096770 0.89 EGFR (0.39) EGFRERBB2ALDH1A1KMT2AMEN1
SCHEMBL3089589 0.89 USP30 (0.42) ALDH1A1TP53USP30
SCHEMBL3092907 0.88 USP30 (0.41) EGFRERBB2L3MBTL1USP30
SCHEMBL3092116 0.88 TARS1 (0.48) LMNA
SCHEMBL3091920 0.87 CCR5 (0.39) USP30RAB9A
SCHEMBL3092864 0.87 LARS1 (0.48) KMT2AMEN1LMNA
SCHEMBL3097806 0.86 FBP1 (0.36) EGFRERBB2USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 — — EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 — — EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 — — US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 — — US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 EGFR 346/4885ERBB2 781/4885ALDH1A1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback